ODE V deputy director
This article was originally published in The Tan Sheet
Executive Summary
Brian Harvey, MD/PhD, appointed deputy director, Office of Drug Evaluation V, effective May 30, FDA announces. Harvey joined FDA in 1995 as a medical officer and has served in clinical review and management positions at both CDRH and CBER. He is involved in FDA interagency collaborations with NIH, CDC and has served as FDA liaison to several professional societies and industry groups, agency notes. Harvey graduated from Middlebury College and received a PhD in biochemistry and an MD at the University of Connecticut. He will report to Jonca Bull, MD, who became director of ODE V roughly a year ago (1"The Tan Sheet" June 3, 2002, p. 13). One of Harvey's first tasks involving the Division of OTC Drug Products could be attending the upcoming NDAC meeting on ipecac...
You may also be interested in...
ODE V Permanent Director Bull Brings Women’s Health, Analgesics Expertise
Jonca Bull, MD, will tackle Rx-to-OTC switch issues head-on in her first week as permanent director of FDA's Office of Drug Evaluation V
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.